New drugs in the management of the irritable bowel syndrome (Q43070882)

13 November 2017

1 reference

title

New drugs in the management of the irritable bowel syndrome (English)

1 reference

13 November 2017

Farthing MJ

1

1 reference

13 November 2017

1 July 1998

1 reference

13 November 2017

1 reference

13 November 2017

56

1 reference

13 November 2017

1

1 reference

13 November 2017

11-21

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199856010-00002

13 November 2017

0 references

cites work

5-HT4 receptor antagonism in irritable bowel syndrome: effect of SB-207266-A on rectal sensitivity and small bowel transit

1 reference

12 December 2020

Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study

1 reference

12 December 2020

Intestinal motor function in irritable bowel syndrome.

1 reference

12 December 2020

Abnormal illness attitudes in patients with irritable bowel syndrome

1 reference

12 December 2020

Effect of a tricyclic antidepressant on small intestinal motility in health and diarrhea-predominant irritable bowel syndrome.

1 reference

12 December 2020

Antidepressants and chronic pain

1 reference

12 December 2020

Inter- and intraindividual variation in pressure-volume relations of the rectum in normal subjects and patients with the irritable bowel syndrome

1 reference

12 December 2020

Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5 HT3-receptor antagonist, in patients with irritable bowel syndrome

1 reference

12 December 2020

Role of cholecystokinin in regulation of gastrointestinal motor functions

1 reference

12 December 2020

Review article: the hypersensitive gut--peripheral kappa agonists as a new pharmacological approach

1 reference

12 December 2020

Intrathecal octreotide for cancer pain

1 reference

12 December 2020

Efficacy of leuprolide in treatment of the irritable bowel syndrome

1 reference

12 December 2020

Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome

1 reference

12 December 2020

Bowel function and transit rate during the menstrual cycle

1 reference

12 December 2020

Effect of a 5HT3-antagonist (ondansetron) on rectal sensitivity and compliance in health and the irritable bowel syndrome.

1 reference

12 December 2020

New or old antidepressants? New is better

1 reference

12 December 2020

Irritable bowel, irritable body, or irritable brain?

1 reference

12 December 2020

A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome

1 reference

12 December 2020

A somatostatin analogue inhibits afferent pathways mediating perception of rectal distention.

1 reference

12 December 2020

Somatostatin and symptomatic relief of irritable bowel syndrome

1 reference

12 December 2020

5-Hydroxytryptamine and human small intestinal motility: effect of inhibiting 5-hydroxytryptamine reuptake

1 reference

12 December 2020

Role of visceral afferent mechanisms in functional bowel disorders

1 reference

12 December 2020

Oral cromolyn sodium in comparison with elimination diet in the irritable bowel syndrome, diarrheic type. Multicenter study of 428 patients

1 reference

12 December 2020

Double-blind study of the effect of cisapride on constipation and abdominal discomfort as components of the irritable bowel syndrome

1 reference

12 December 2020

Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia?

1 reference

12 December 2020

Effect of leuprolide acetate in patients with moderate to severe functional bowel disease. Double-blind, placebo-controlled study

1 reference

12 December 2020

5-Hydroxytryptamine and 5-Hydroxytryptamine-3 Receptor Antagonists

1 reference

12 December 2020

Food intolerance and the irritable bowel syndrome

1 reference

12 December 2020

Intrathecal and epidural somatostatin in rats: can antinociception, motor effects and neurotoxicity be separated?

1 reference

12 December 2020

Effect of octreotide on mouth-to-caecum transit time in healthy subjects and in the irritable bowel syndrome.

1 reference

12 December 2020

Controlled treatment trials in the irritable bowel syndrome: a critique.

1 reference

12 December 2020

A controlled trial of psychological treatment for the irritable bowel syndrome

1 reference

12 December 2020

Loxiglumide, a CCK-A Antagonist, in Irritable Bowel Syndrome

1 reference

12 December 2020

Hypnotherapy in severe irritable bowel syndrome: further experience

1 reference

12 December 2020

Bran and irritable bowel syndrome: time for reappraisal

1 reference

12 December 2020

A population study of food intolerance

1 reference

12 December 2020

Selective affective biasing in recognition memory in the irritable bowel syndrome

1 reference

12 December 2020

Oral disodium cromoglycate treatment on irritable bowel syndrome: an open study on 101 subjects with diarrheic type

1 reference

12 December 2020

Calcium polycarbophil compared with placebo in irritable bowel syndrome.

1 reference

12 December 2020

Non-colonic features of irritable bowel syndrome

1 reference

12 December 2020

Effect of leuprolide acetate in patients with functional bowel disease. Long-term follow-up after double-blind, placebo-controlled study

1 reference

12 December 2020

Patients with irritable bowel syndrome have greater pain tolerance than normal subjects

1 reference

12 December 2020

Towards positive diagnosis of the irritable bowel

1 reference

12 December 2020

Meta-analyses of randomized controlled trials.

1 reference

12 December 2020

Intraventricular somatostatin-14, arginine vasopressin, and oxytocin: analgesic effect in a patient with intractable cancer pain.

1 reference

12 December 2020

10.2165/00003495-199856010-00002

Identifiers

DOI

1 reference

PubMed ID

9664195

Dimensions Publication ID

13 November 2017

0 references

1 reference

PubMed ID

9664195